WO2003028717A1 - A drugs association against influenza virus - Google Patents
A drugs association against influenza virus Download PDFInfo
- Publication number
- WO2003028717A1 WO2003028717A1 PCT/EP2002/008584 EP0208584W WO03028717A1 WO 2003028717 A1 WO2003028717 A1 WO 2003028717A1 EP 0208584 W EP0208584 W EP 0208584W WO 03028717 A1 WO03028717 A1 WO 03028717A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ribavirin
- nac
- influenza virus
- association
- against influenza
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 title abstract description 6
- 241000712461 unidentified influenza virus Species 0.000 title abstract description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract description 20
- 229960000329 ribavirin Drugs 0.000 claims abstract description 20
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims abstract description 20
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002648 combination therapy Methods 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract description 19
- 206010022000 influenza Diseases 0.000 abstract description 9
- 229960004308 acetylcysteine Drugs 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 229940077952 ribavirin 100 mg Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000776474 Patescibacteria group Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
Definitions
- the present invention relates to a drugs association against flu virus and more particularly it relates to the association of N-acetyl-cysteine and Ribavirin and the use of that association to treat influenza virus disease.
- N-acetyl-cysteine (The Merck Index, XII Ed., page 16, No. 89) is a known drug with mucolitic and anti-oxidant activity. Among the various properties of the molecule, a certain activity to protect the laboratory animals infected with the flu virus has been described. Ribavirin (The Merck Index, XII Ed., page 1409, No. 8365) is a known drug with antiviral activity.
- NAC N-acetyl-cysteine
- Ribavirin even if it has meaningful antiviral properties, is not completely effective against flu virus [Antimicrobial Agents and Chemotherapy, 31(8), 1285 (1987)].
- NAC can increase significatively and in a synergistic manner the antiviral activity of Ribavirin.
- Object of the present invention therefore is a pharmaceutical composition containing NAC and Ribavirin to antagonise flu virus by increasing Ribavirin efficacy.
- a second object of the present invention is the use of NAC for preparing pharmaceutical compositions to administer in combined therapy with Ribavirin to antagonise flu virus.
- a third object of the present invention is a kit containing an effective amount of
- NAC and Ribavirin or multiples thereof, in a form for administration are provided.
- compositions object of the invention are preferably those suitable by oral administration (tablets, capsules, syrups, water-soluble forms), by aerosol (especially ready or extemporaneous solutions to be administered by suitable inhalers) or by injective route (ready solutions or to be prepared at the moment of use from lyophilized).
- the doses which will change following to the selected pharmaceutical form, the seriousness of the infection and the patient response, will ensure an amount of Ribavirin between 1 and 5 g/die and of NAC between 1,2 and 6 g/die.
- Example 1 Effect of NAC and Ribavirin association on the lethality of flu virus in mice
- the animals were infected intranasally with a viral flu suspension (strain PR/8, suspension in 0.05 ml of culture medium) in a dose of 2-3 LD 50 and therefore they were randomly assigned (12 animals each group) to the following groups:
- Group 1 treated with vehicle (physiological solution) per os or intraperitoneal without active ingredients
- Group 2 treated with Ribavirin 100 mg/kg i.p.
- Group 3 treated with NAC 1000 mg/kg p.o.
- Group 4 treated with Ribavirin 100 mg/kg i.p. and NAC 1000 mg/kg p.o. Treatments (once daily) were started 4 hours after the infections and prolonged for 4 days. The animals were observed until the 14 th day and the total number of the dead animals were registered day by day.
- Example 2 A kit for aerosol comprising a solution of Ribavirin at 20 mg/ml concentration and a solution of NAC 10% was prepared.
- the kit contains also the instructions for use, suitable instruments to open the vials containing the solutions and if need a small bottle where to mix the solutions before administering the aerosol.
- Example 3 A kit containing Ribavirin in injectable solution (1200 mg) and effervescent tablets of NAC (2x600 mg, FLUIMUCIL ® ) was prepared.
- the kit contains the instructions for use and a sterilized syringe for i.v. injection of Ribavirin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A drugs association against flu virus and more particularly the association of N-acetyl-cysteine and Ribavirin and the use of that association to treat influenza virus disease is described.
Description
A DRUGS ASSOCIATION AGAINST INFLUENZA VIRUS
The present invention relates to a drugs association against flu virus and more particularly it relates to the association of N-acetyl-cysteine and Ribavirin and the use of that association to treat influenza virus disease.
N-acetyl-cysteine (The Merck Index, XII Ed., page 16, No. 89) is a known drug with mucolitic and anti-oxidant activity. Among the various properties of the molecule, a certain activity to protect the laboratory animals infected with the flu virus has been described. Ribavirin (The Merck Index, XII Ed., page 1409, No. 8365) is a known drug with antiviral activity.
N-acetyl-cysteine (from now on briefly indicated as NAC) does not have an antiviral activity such as to be effectively used it alone for this aim.
Ribavirin, even if it has meaningful antiviral properties, is not completely effective against flu virus [Antimicrobial Agents and Chemotherapy, 31(8), 1285 (1987)].
We have surprisingly found that NAC can increase significatively and in a synergistic manner the antiviral activity of Ribavirin.
Object of the present invention therefore is a pharmaceutical composition containing NAC and Ribavirin to antagonise flu virus by increasing Ribavirin efficacy. A second object of the present invention is the use of NAC for preparing pharmaceutical compositions to administer in combined therapy with Ribavirin to antagonise flu virus.
Furthermore, a third object of the present invention is a kit containing an effective amount of
NAC and Ribavirin or multiples thereof, in a form for administration.
The pharmaceutical compositions object of the invention are preferably those suitable by oral administration (tablets, capsules, syrups, water-soluble forms), by aerosol (especially ready or extemporaneous solutions to be administered by suitable inhalers) or by injective route (ready solutions or to be prepared at the moment of use from lyophilized).
The doses, which will change following to the selected pharmaceutical form, the seriousness of the infection and the patient response, will ensure an amount of Ribavirin between 1 and 5 g/die and of NAC between 1,2 and 6 g/die.
To better illustrate the present invention but without limiting it, the following examples are
now given.
Example 1 Effect of NAC and Ribavirin association on the lethality of flu virus in mice The animals were infected intranasally with a viral flu suspension (strain PR/8, suspension in 0.05 ml of culture medium) in a dose of 2-3 LD50 and therefore they were randomly assigned (12 animals each group) to the following groups:
Group 1: treated with vehicle (physiological solution) per os or intraperitoneal without active ingredients
Group 2; treated with Ribavirin 100 mg/kg i.p. Group 3: treated with NAC 1000 mg/kg p.o.
Group 4: treated with Ribavirin 100 mg/kg i.p. and NAC 1000 mg/kg p.o. Treatments (once daily) were started 4 hours after the infections and prolonged for 4 days. The animals were observed until the 14th day and the total number of the dead animals were registered day by day.
The test results are reported in the following Table 1. Table 1 Effect of NAC and Ribavirin on the lethality of flu virus in mouse.
Example 2 A kit for aerosol comprising a solution of Ribavirin at 20 mg/ml concentration and a solution
of NAC 10% was prepared.
The kit contains also the instructions for use, suitable instruments to open the vials containing the solutions and if need a small bottle where to mix the solutions before administering the aerosol.
Example 3 A kit containing Ribavirin in injectable solution (1200 mg) and effervescent tablets of NAC (2x600 mg, FLUIMUCIL®) was prepared.
The kit contains the instructions for use and a sterilized syringe for i.v. injection of Ribavirin.
Claims
1. A pharmaceutical composition containing NAC and Ribavirin to antagonise the flu virus by increasing the efficacy of Ribavirin.
2. Use of NAC to prepare a pharmaceutical composition to be administered in combined therapy with Ribavirin to antagonise the flu virus.
3. A kit containing an effective amount of NAC and Ribavirin or multiples thereof, and a form for administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02800058A EP1505991A1 (en) | 2001-09-05 | 2002-08-01 | A drugs association against influenza virus |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI001863A ITMI20011863A1 (en) | 2001-09-05 | 2001-09-05 | ASSOCIATION OF DRUGS AGAINST THE VIRUS OF INFLUENCE |
| ITMI01A001863 | 2001-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003028717A1 true WO2003028717A1 (en) | 2003-04-10 |
Family
ID=11448332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2002/008584 WO2003028717A1 (en) | 2001-09-05 | 2002-08-01 | A drugs association against influenza virus |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1505991A1 (en) |
| IT (1) | ITMI20011863A1 (en) |
| WO (1) | WO2003028717A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4142774A4 (en) * | 2020-05-01 | 2024-05-29 | Mucpharm Pty Ltd | Preventing and treating viral infections |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008540A1 (en) * | 1989-01-26 | 1990-08-09 | Zambon Group S.P.A. | Treatment of disease associated with hiv-infections |
| US5580577A (en) * | 1990-01-11 | 1996-12-03 | Herzenberg; Leonard A. | Method of treating the symptoms of human rhinovirus infection |
| WO1998030228A1 (en) * | 1997-01-13 | 1998-07-16 | Emory University | Compounds and their combinations for the treatment of influenza infection |
| EP1046399A1 (en) * | 1999-04-19 | 2000-10-25 | Schering Corporation | HCV combination therapy, containing ribavirin in association with antioxidants |
-
2001
- 2001-09-05 IT IT2001MI001863A patent/ITMI20011863A1/en unknown
-
2002
- 2002-08-01 WO PCT/EP2002/008584 patent/WO2003028717A1/en active Application Filing
- 2002-08-01 EP EP02800058A patent/EP1505991A1/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008540A1 (en) * | 1989-01-26 | 1990-08-09 | Zambon Group S.P.A. | Treatment of disease associated with hiv-infections |
| US5580577A (en) * | 1990-01-11 | 1996-12-03 | Herzenberg; Leonard A. | Method of treating the symptoms of human rhinovirus infection |
| WO1998030228A1 (en) * | 1997-01-13 | 1998-07-16 | Emory University | Compounds and their combinations for the treatment of influenza infection |
| EP1046399A1 (en) * | 1999-04-19 | 2000-10-25 | Schering Corporation | HCV combination therapy, containing ribavirin in association with antioxidants |
Non-Patent Citations (3)
| Title |
|---|
| FLORA DE S ET AL: "ATTENUATION OF INFLUENZA-LIKE SYMPTOMATOLOGY AND IMPROVEMENT OF CELL-MEDIATED IMMUNITY WITH LONG-TERM N-ACETYLCYSTEINE TREATMENT", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 10, July 1997 (1997-07-01), pages 1535 - 1541, XP002912424, ISSN: 0903-1936 * |
| HENNET T ET AL: "ALTERATIONS IN ANTIOXIDANT DEFENCES IN LUNG AND LIVER OF MICE INFECTED WITH INFLUENZA A VIRUS", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 73, January 1992 (1992-01-01), pages 39 - 46, XP002912421, ISSN: 0022-1317 * |
| TODISCO T ET AL: "PROTECTIVE EFFECT OF N-ACETYLCYSTEINE ON IMMUNE SYSTEM OF ELDERLY PATIENTS IN ACUTE REPIRATORY VIRAL INFECTIONS", ANNUAL CONGRESS. EUROPEAN RESPIRATORY SOCIETY ERS. ABSTRACTS, XX, XX, 25 September 1993 (1993-09-25), pages 559S, XP002912419 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4142774A4 (en) * | 2020-05-01 | 2024-05-29 | Mucpharm Pty Ltd | Preventing and treating viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20011863A1 (en) | 2003-03-05 |
| EP1505991A1 (en) | 2005-02-16 |
| ITMI20011863A0 (en) | 2001-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5209180B2 (en) | Treatment of avian influenza infection | |
| US20150374759A1 (en) | Method for Treatment of Sores and Lesions of the Skin | |
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| EA037085B1 (en) | Stuffy nose deblocking composition having antiviral activity | |
| JPH06505231A (en) | Use of quinones in the treatment of cancer or AIDS | |
| Sidwell et al. | Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice | |
| WO2021198940A1 (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| CA2465062C (en) | Preventive and/or therapeutic agent for viral infection | |
| CN1965844A (en) | Nasal administered pharmaceutical composition containing glycyrrhetic acid and medical use thereof | |
| EP1505991A1 (en) | A drugs association against influenza virus | |
| CN114762694B (en) | Use of oligosaccharide transferase inhibitors for the prevention and/or treatment of novel coronavirus infections | |
| CN101062066A (en) | Compound isatis-root injection for animals and the preparing method thereof | |
| EP0576506B1 (en) | Use of benzimidazole anthelmintic in the treatment of microsporidial infections | |
| WO2007106675A2 (en) | Composition and method of retarding viral activity and reducing viral replication | |
| CN1432357A (en) | Fever allaying prepn containing xylitol | |
| RU2103997C1 (en) | Medicinal agent for treatment of animal disease of bacterial etiology, method of treatment of animal gastroenteric disease of bacterial etiology and methods of treatment of gynecological disease of bacterial etiology in animals | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection | |
| KR101825090B1 (en) | Pharmaceutical Composition Comprising Ribavirin Or Derivatives Thereof For Treating Foot-And-Mouth Disease | |
| WO2024005747A1 (en) | Antiviral nasal spray | |
| RU2223755C1 (en) | Method for treating equine relapsing iridocyclochorioiditis | |
| RU2146147C1 (en) | Antiparasitic preparation of prolonged action | |
| US20240269222A1 (en) | Composition for respiratory diseases | |
| WO2022216172A1 (en) | Aqueous aprotinin-containing antiviral pharmaceutical composition | |
| RU2223756C1 (en) | Method for treating equine relapsing iridocyclochorioiditis | |
| US20230210844A1 (en) | Pharmaceutical combination having potent antiviral activity against single-stranded rna viruses including coronaviruses and monkeypox |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR US |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2002800058 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002800058 Country of ref document: EP |